The reversible dementia project (Q4298273)
Jump to navigation
Jump to search
Project Q4298273 in France, United Kingdom
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The reversible dementia project |
Project Q4298273 in France, United Kingdom |
Statements
2,493,753.75 Euro
0 references
3,614,135.87 Euro
0 references
69.0 percent
0 references
1 October 2020
0 references
30 June 2023
0 references
University of Cambridge
0 references
49°12'21.78"N, 0°21'42.08"W
0 references
49°53'38.65"N, 2°17'44.70"E
0 references
52°11'11.08"N, 0°8'15.86"E
0 references
52°7'39.29"N, 0°10'39.47"E
0 references
48°23'34.01"N, 4°29'10.25"W
0 references
49°52'34.46"N, 2°16'0.62"E
0 references
50°17'6.22"N, 2°47'27.24"E
0 references
1.Dementia is a devastating condition that tends to affect the elderly. Care for dementia sufferers is costly and is an increasing challenge facing the FCE area (challenge 2). The average annual costs of dementia care per affected person in the UK is estimated at £32250 [2], and in France €22099. [3]. French Alzheimer society quotes 1.2 million people affected, and rising with an ageing population. 2.Normal pressure hydrocephalus (NPH) is a form of dementia caused by impairment of the circulation of the fluid that bathes the brain and spine (CSF) [1]. Unlike Alzheimer’s disease, it can be potentially reversed by surgically implanting a shunt. This is important because 5-15% (that’s 65-200k, given figures above) of dementia patients are misdiagnosed with Alzheimer’s and should instead be treated for NPH [5–7].The aim of the project is to implement innovative medical tools developed by individual partners to diagnose NPH patients quickly and accurately as part of an integrated care pathway. These include diagnostic software for interpreting MRI imaging and CSF pressure dynamics, and a web-based portal for patient referrals and ongoing management. The expected impact is to reduce hospital stay (1 day from 3-5 days) and associated risks of hospitalisation, and improve patient experience and well-being. Improving diagnostic efficiency of NPH will increase patients diagnosed with the condition and therefore improve their chances of leading a more independent life, with significant predicted cost savings (hundreds of millions € annually) on future health and social care provision (see the cover letter). 3.The cross-border collaboration, combining world-leading expertise of Amiens (brain flow diagnostics) and Cambridge (brain pressure), is essential for successful delivery. We will also explore further diagnostic refinements using AI, drawing on the experience of our partners in Lens. Our commercial partner has extensive expertise in secure multi-site healthcare data sharing (Obex). The integrated pathway will be evaluated in hospitals within the region, 4 pilot sites: Cambridge, Amiens, Caen and Brest. 4.The results of the project have the potential to be sustained and significant. Neurosurgical centres in the Area will be able to integrate the new diagnostic suite into their everyday practice with direct benefits to their patients. Dissemination of the outputs and technology outside of the programme area will have a positive impact on a wider population and achieve a real measurable medical change. In particular a collection of consensus guidelines, protocols and standards developed will guide the implementation of best practice in the Area and beyond. 5.The project outputs will also reinforce the recognition of the programme area as a region of excellence in medical innovation. Ultimately, it will help to increase the quality of life for a significant proportion of over 65s affected by this under-reported debilitating illness. (English)
0 references